Aytu BioPharma Management
Management criteria checks 2/4
Aytu BioPharma's CEO is Josh Disbrow, appointed in Apr 2015, has a tenure of 7.25 years. total yearly compensation is $567.31K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth €123.42K. The average tenure of the management team and the board of directors is 0.4 years and 6.9 years respectively.
Key information
Josh Disbrow
Chief executive officer
US$567.3k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 8yrs |
| CEO ownership | 1.6% |
| Management average tenure | less than a year |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | n/a | n/a | -US$78m |
| Sep 30 2022 | n/a | n/a | -US$83m |
| Jun 30 2022 | US$567k | US$567k | -US$110m |
| Mar 31 2022 | n/a | n/a | -US$111m |
| Dec 31 2021 | n/a | n/a | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | US$6m | US$545k | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | US$2m | US$608k | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$25m |
| Dec 31 2019 | n/a | n/a | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$29m |
| Jun 30 2019 | US$1m | US$330k | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$12m |
| Dec 31 2018 | n/a | n/a | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | US$606k | US$303k | -US$10m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | n/a | n/a | -US$20m |
| Sep 30 2017 | n/a | n/a | -US$21m |
| Jun 30 2017 | US$1m | US$250k | -US$23m |
| Mar 31 2017 | n/a | n/a | -US$31m |
| Dec 31 2016 | n/a | n/a | -US$33m |
| Sep 30 2016 | n/a | n/a | -US$32m |
| Jun 30 2016 | US$1m | US$250k | -US$28m |
Compensation vs Market: Josh's total compensation ($USD567.31K) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.
CEO
Josh Disbrow (47 yo)
8yrs
Tenure
US$567,308
Compensation
Mr. Joshua R. Disbrow, also known as Josh, is Chairman of the Board at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 and serves as its Chief Executive Officer. He serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 8yrs | US$567.31k | 1.61% € 123.4k | |
| CFO, Secretary & Treasurer | 1.3yrs | US$352.60k | 0.27% € 20.4k | |
| Chief Operating Officer | less than a year | no data | 1.63% € 125.1k | |
| Vice President of People & Culture | less than a year | no data | no data | |
| Chief Business Officer & President of Consumer Health | less than a year | US$793.41k | 0.36% € 27.4k | |
| Chief Commercial Officer | no data | no data | 0.25% € 19.5k | |
| Senior Vice President of Research & Development | no data | no data | no data | |
| Executive VP of Finance & Business Optimization | less than a year | no data | no data |
0.4yrs
Average Tenure
47yo
Average Age
Experienced Management: AY20's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.3yrs | US$567.31k | 1.61% € 123.4k | |
| Independent Director | less than a year | no data | 0.19% € 14.6k | |
| Lead Independent Director | 6.8yrs | US$75.00k | 0.021% € 1.6k | |
| Independent Director | 7yrs | US$70.00k | 0.21% € 15.9k |
6.9yrs
Average Tenure
57yo
Average Age
Experienced Board: AY20's board of directors are considered experienced (6.9 years average tenure).